Heron Therapeutics News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

11.11.24	Ausblick: Heron Therapeutics gibt Ergebnis zum abgelaufenen Quartal bekannt (finanzen.net)
25.09.24	Heron Therapeutics' Zynrelef Vial Access Needle Receives FDA Approval (RTTNews)
02.09.24	Biotech Stocks Facing FDA Decision In September 2024 (RTTNews)
05.08.24	Ausblick: Heron Therapeutics präsentiert Quartalsergebnisse (finanzen.net)
29.05.24	Heron Therapeutics Submits Prior Approval Supplement To FDA For Zynrelef VAN (RTTNews)
07.05.24	Heron Therapeutics Inc. Q1 Loss decreases, beats estimates (RTTNews)
06.05.24	Ausblick: Heron Therapeutics stellt das Zahlenwerk zum vergangenen Quartal vor (finanzen.net)
11.03.24	Ausblick: Heron Therapeutics veröffentlicht Zahlen zum vergangenen Quartal (finanzen.net)
24.01.24	Heron : FDA Oks ZYNRELEF Indication Expansion To Include Addl. Orthopedic & Soft Tissue Procedures (RTTNews)
08.01.24	Heron Therapeutics Partners With CrossLink Life Sciences To Expand Promotional Effort For Zynrelef (RTTNews)
14.11.23	Heron Therapeutics Announces Third Quarter 2023 Financial Results and Updates Financial Guidance (PR Newswire)
13.11.23	Ausblick: Heron Therapeutics gibt Ergebnis zum abgelaufenen Quartal bekannt (finanzen.net)
07.11.23	Heron Therapeutics to Report Third Quarter 2023 Financial Results On Tuesday, November 14, 2023 (PR Newswire)
14.08.23	Heron Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Updates (PR Newswire)
13.08.23	Ausblick: Heron Therapeutics präsentiert Quartalsergebnisse (finanzen.net)
07.08.23	Heron Therapeutics to Report Second Quarter 2023 Financial Results on Monday, August 14, 2023 (PR Newswire)
24.07.23	Heron Therapeutics Announces Cost Reduction Plan - Quick Facts (RTTNews)
24.07.23	Heron Therapeutics Announces Cost Reduction Plan and Restructuring (PR Newswire)
24.07.23	Heron Therapeutics Announces $30 Million Private Placement Financing (PR Newswire)
23.06.23	Heron Therapeutics Announces Appointment of Ira Duarte as Chief Financial Officer (PR Newswire)
12.06.23	Heron Therapeutics Announces Appointment of William Forbes, Pharm.D. as Chief Development Officer (PR Newswire)
11.05.23	Heron Therapeutics Announces Financial Results for the Three Months Ended March 31, 2023 and Highlights Recent Corporate Updates (PR Newswire)
10.05.23	Ausblick: Heron Therapeutics stellt das Zahlenwerk zum vergangenen Quartal vor (finanzen.net)
04.05.23	Heron Therapeutics to Report First Quarter 2023 Financial Results on Thursday, May 11, 2023 (PR Newswire)
20.04.23	Heron Therapeutics Announces Commercial Leadership Changes (PR Newswire)
17.04.23	Heron Therapeutics Announces Presentation at 22nd Annual Needham Virtual Healthcare Conference (PR Newswire)
03.04.23	Heron Therapeutics Appoints Craig Collard CEO, Adam Morgan Chairman (RTTNews)
03.04.23	Heron Therapeutics Announces New CEO and Board Chairman (PR Newswire)
23.03.23	Heron Therapeutics Announces Financial Results for the Three and Twelve Months Ended December 31, 2022 and Highlights Recent Corporate Updates (PR Newswire)
13.03.23	Heron Therapeutics Announces Centers for Medicare & Medicaid Services (CMS) Granted Pass-through Payment Status for APONVIE™, Effective April 1, 2023 (PR Newswire)
10.03.23	Heron Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 23, 2023 (PR Newswire)
06.03.23	Heron Therapeutics Announces U.S. Commercial Launch of APONVIE™ for the Management of Postoperative Nausea and Vomiting in Adults (PR Newswire)
27.02.23	Heron Therapeutics Announces Presentation at 43rd Annual Cowen Healthcare Conference (PR Newswire)
23.02.23	Pre-market Movers: LUNR, GSM, CALT, ENVX, HRTX… (RTTNews)
22.02.23	Heron Therapeutics Enters into Cooperation Agreement with Rubric Capital and Velan Capital (PR Newswire)
09.01.23	Heron Therapeutics Highlights Progress in Acute Care and Oncology Care Franchises (PR Newswire)
29.12.22	Heron Therapeutics Announces Filing of an Efficacy Supplement for ZYNRELEF® and Provision in Newly Passed Congressional Bill Anticipated to Provide Separate Reimbursement Outside of the Packaged S... (PR Newswire)
21.11.22	Heron Therapeutics Announces Virtual Presentation at Evercore ISI 5th Annual HealthCONx Conference (PR Newswire)
08.11.22	Heron Therapeutics Announces Financial Results for the Three and Nine Months Ended September 30, 2022 and Highlights Recent Corporate Updates (PR Newswire)
07.11.22	Ausblick: Heron Therapeutics verkündet Quartalsergebnis zum jüngsten Jahresviertel (finanzen.net)
01.11.22	Heron Therapeutics to Report Third Quarter 2022 Financial Results on Tuesday, November 8, 2022 (PR Newswire)
17.09.22	Heron Therapeutics: FDA Approves APONVIE For Prevention Of Postoperative Nausea, Vomiting In Adults (RTTNews)
16.09.22	Heron Therapeutics Announces U.S. FDA Approval of APONVIE™ (HTX-019) for the Prevention of Postoperative Nausea and Vomiting (PONV) (PR Newswire)
27.08.22	Biotech Stocks Facing FDA Decision In September (RTTNews)
09.08.22	Heron Therapeutics Announces $76.5 Million Private Placement Financing (PR Newswire)
09.08.22	Heron Therapeutics Announces Financial Results for the Three and Six Months Ended June 30, 2022 and Highlights Recent Corporate Updates (PR Newswire)
08.08.22	Ausblick: Heron Therapeutics verkündet Quartalsergebnis zum jüngsten Jahresviertel (finanzen.net)
02.08.22	Heron Therapeutics to Report Second Quarter 2022 Financial Results on Tuesday, August 9, 2022 (PR Newswire)
30.06.22	Heron Therapeutics To Axe 34% Jobs (RTTNews)
30.06.22	Heron Therapeutics Announces Restructuring and Cost Reduction Plan to Address Market Dynamics and Prepare for Long-Term Sustainability (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Logitech Intl	77.78	3.85 %	K V
CieFinRichemont	139.05	3.58 %	K V
UBS Group	29.21	2.64 %	K V
Sika	217.70	2.25 %	K V
Lonza Grp	541.80	1.46 %	K V
Swiss Re	132.60	-0.08 %	K V
Swisscom	504.00	-0.10 %	K V
Sonova Hldg	294.30	-0.71 %	K V
Nestle	74.02	-0.91 %	K V
Givaudan	3’888.00	-1.44 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Heron Therapeutics Inc

Aktien Top/Flop

Meistgelesene Nachrichten